BridgeMD
New treatment option for Ovarian Epithelial Cancer
Official title Timing of Surgery After Neoadjuvant Chemotherapy for Advanced Ovarian Cancer
ClinicalTrials.gov ID: NCT06404671
What this study is testing
- What it's testing
- Ovarian cancer is among the top five primary causes of cancer-related mortality in women. Most ovarian malignant tumours originate from epithelial cells The majority of patients typically have advanced-stage tumours at diagnosis.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75, women only
You may be able to join if
- Female Patients aged 18 to 75 years.
- International Federation of Gynecology and Obstetrics (FIGO) stage IIIB-IV unsuitable for UCS.
- Histologically confirmed high-grade serous (HGS) ovarian, fallopian tube, or primary peritoneal carcinoma.
- ECOG performance status: 0 or 1.
- Resectable disease by laparoscopic assessment after 3 cycles of NACT.
You likely can't join if
- Metastatic ovarian carcinoma.
- Patients with primary ovarian carcinoma other than high-grade serous (low-grade serous, endometrioid, mucinous, clear cell, and non-epithelial...
- Presence of pregnancy or breast-feeding.
- History of other invasive malignancies in the previous 5 years.
- History of a recent \< 6 month cerebrovascular accident.
- Uncontrolled systemic disease or contraindication to chemotherapy.
See the full eligibility criteria
- Female Patients aged 18 to 75 years.
- International Federation of Gynecology and Obstetrics (FIGO) stage IIIB-IV unsuitable for UCS.
- Histologically confirmed high-grade serous (HGS) ovarian, fallopian tube, or primary peritoneal carcinoma.
- ECOG performance status: 0 or 1.
- Resectable disease by laparoscopic assessment after 3 cycles of NACT.
- Adequate haematology, bone marrow, respiratory, hepatic, cardiac and renal functions.
- Estimated life expectancy of \> 3 months according to Age-adjusted Charlston Co-morbidity Index (ACCI), included patients should have a low or intermediate comorbidity score; ACCI 0-3.
- Metastatic ovarian carcinoma.
- Patients with primary ovarian carcinoma other than high-grade serous (low-grade serous, endometrioid, mucinous, clear cell, and non-epithelial ovarian carcinoma).
- Presence of pregnancy or breast-feeding.
- History of other invasive malignancies in the previous 5 years.
- History of a recent \< 6 month cerebrovascular accident.
- Uncontrolled systemic disease or contraindication to chemotherapy.
- Progressive disease on NACT.
- Worsening Eastern Cooperative Oncology Group (ECOG) Performance Status (ECOG 2-4).
- Severe comorbidities (ACCI \>= 4)
The study team makes the final eligibility decision.
Where it's taking place
- Alexandria, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Alexandria, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.